| SC 13D/A | 2024-01-04 | Cambridge Equities, LP | ImmunityBio, Inc. | 261,705,814 | 39.0% | EDGAR |
| SC 13D/A | 2023-09-21 | Cambridge Equities, LP | ImmunityBio, Inc. | 261,705,814 | 39.2% | EDGAR |
| SC 13D/A | 2023-05-23 | Cambridge Equities, LP | ImmunityBio, Inc. | 261,705,814 | 60.0% | EDGAR |
| SC 13D/A | 2022-12-07 | Cambridge Equities, LP | ImmunityBio, Inc. | 261,705,814 | 65.4% | EDGAR |
| SC 13D/A | 2021-03-12 | Cambridge Equities, LP | ImmunityBio, Inc. | 261,705,814 | 68.4% | EDGAR |
| SC 13D/A | 2020-12-21 | Cambridge Equities, LP | NantKwest, Inc. | 40,575,814 | 37.4% | EDGAR |
| SC 13D/A | 2020-06-29 | Cambridge Equities, LP | NantKwest, Inc. | 40,575,814 | 37.9% | EDGAR |
| SC 13D/A | 2019-04-01 | Cambridge Equities, LP | NantKwest, Inc. | 40,575,814 | 41.2% | EDGAR |
| SC 13G/A | 2018-02-13 | Wildcat Capital Management, LLC | NantKwest, Inc. | 808,974 | 1.0% | EDGAR |
| SC 13G | 2018-02-13 | Simon Barry J. | NantKwest, Inc. | 4,685,077 | 5.9% | EDGAR |
| SC 13G/A | 2017-02-13 | Sorrento Therapeutics, Inc. | NantKwest, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2016-07-11 | Cambridge Equities, LP | NantKwest, Inc. | 41,025,814 | 50.0% | EDGAR |
| SC 13G | 2016-02-17 | Sorrento Therapeutics, Inc. | NantKwest, Inc. | 5,618,326 | 6.9% | EDGAR |
| SC 13G | 2016-02-12 | Bonderman Family Limited Partnership | NantKwest, Inc. | 4,485,495 | 5.5% | EDGAR |
| SC 13D/A | 2015-10-23 | Cambridge Equities, LP | NantKwest, Inc. | 43,025,814 | 51.7% | EDGAR |
| SC 13D | 2015-08-31 | Cambridge Equities, LP | NantKwest, Inc. | 41,007,300 | 51.8% | EDGAR |